MDx Impact Grants

The MDx Impact Grants, sponsored by Springer Nature Limited, aim to enhance access to PCR-based diagnostic tests that can significantly improve patient outcomes. Research groups worldwide are invited to collaborate with Seegene to develop tests targeting Urinary Tract Infection (UTI) Drug Resistance genes. Eligible applicants can receive grants up to 600,000 USD to conduct clinical studies, focusing on critical antibiotic resistance genes like CTX-M and KPC. This initiative strives to address unmet clinical needs effectively.

The MDx Impact Grants aim to unlock the potential of PCR to democratise access to accurate diagnostic tests that improve patient outcomes.
We invite research groups to work with us and our partner Seegene to develop tests that address unmet clinical needs. The programme provides researchers with access to Seegene’s syndromic PCR technology and development grants of up to 600,000 USD to perform clinical studies.
Each research group is permitted to submit only one application focused on the designated project. We welcome applications from eligible research groups from around the world.
Urinary Tract Infection (UTI) Drug Resistance (DR)
This year, the MDx Impact Grants focus on Urinary Tract Infection (UTI) Drug Resistance (DR) genes that correspond to clinically important antibiotic resistance genes, such as, CTX-M, KPC, NDM and vanA. Your proposal must include a minimum of nine (9) and up to a maximum of eighteen (18) target genes excluding internal controls.

Eligibility

Prior to drafting your grant application, you will be asked to confirm you meet the eligibility requirements for this grant. The eligibility criteria are shown below:Have access to a laboratory with BSL-2 (Biosafety level 2) or higher, capable of performing the proposed clinical studies.Have a research team consisting of two or more qualified researchers or plans to hire. Have experience in PCR. Possess or have access to both positive and negative clinical specimens or have a collection plan.Employed by or affiliated with a university, research institution, and clinical laboratory, or other similar organisations. Eligible to conduct the proposed clinical studies appropriate for regulatory approval.Hold a doctorate or medical degree (e.g., PhD, MD, PharmD).Applicants can be of any nationality and projects can be hosted at eligible organisations in any country

Ineligibility

From Cuba, Iran, North Korea, Sudan, Syria, Burma/Myanmar, Niger, Russia, Belarus, or the Crimea, Donetsk or Luhansk regions of Ukraine, or other sanction-sensitive countries or regions as updated from time to time.